2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Microbiome, Clinical Practice (Health Services and Quality), Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, LGL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly
PAPER

1839 Trial in progress: Phase II study of ruxolitinib and pembrolizumab in relpased/refractory T-cell lymphoomas (Amping Up with PemJak)

Seda S. Tolu, MD, Ted Piorczynski, PhD2, David DeStephano3, Manuel Pazos, BS, MS4, Naomi Sender5, Carmela Turco6, Beatriz Raposo Corradini, MSc7, Jaspreet Wadhwa8, Alexandra Coromilas9, Alexander D. Sanjurjo, B.S.10, Jia Ruan, MD, PhD11, Hua-Jay Jeffery Cherng, MD12, Alejandro Gru, MD13, Larisa J. Geskin, MD14, Barbara Pro, MD15, Jennifer Effie Amengual, MD16
1 Columbia University Irving Medical Center, New York, United States
2 Columbia University Irving Medical Center, New York, United States
3 Columbia University Irving Medical Center, New York, United States
4 Columbia University Irving Medical Center, New York, United States
5 Columbia University Irving Medical Center, New York, United States
6 Columbia University Irving Medical Center, New York, United States
7 Columbia University Irving Medical Center, New York, United States
8 Columbia University Irving Medical Center, New York, United States
9 Columbia University Irving Medical Center, New York, United States
10 Columbia University Irving Medical Center, New York, United States
11 Weill Cornell/ Sandra and Edward Meyer Cancer Center, New York, New York, United States
12 Columbia University Irving Medical Center, New York, United States
13 Columbia University Irving Medical Center, New York, United States
14 Columbia University Irving Medical Center, New York, United States
15 Columbia University Irving Medical Center, New York, United States
16 Columbia University Irving Medical Center, New York, United States
Background/Significance: Preclinical studies demonstrate ruxolitinib (JAK1/2 inhibitor) modulates immunogenicity via reduction of PDL-1/-2 on tumor cells and decreases cell growth via reduction of C-MYC. In the tumor microenvironment (TME), ruxolitinib, increases intra-tumoral CD8+ T-cell infiltration, increases NK-cell abundance, and decreases myeloid-derived suppressor cells, collectively creating a more activated immune microenvironment. Combination with ruxolitinib and pembrolizumab (PD-1 inhibitor) produced greater tumor death and prolonged survival in murine lymphoma models (Tolu ASH 2024). Therapeutic implications of ruxolitinib and pembrolizumab are particularly relevant to lymphomas that rely on immune escape pathways and JAK/STAT activation for growth and survival including T-cell lymphomas and 9p24.1 amplified lymphomas. From available phase II data, treatment with pembrolizumab alone has achieved modest overall response rates (ORR) in cutaneous T-cell lymphoma (CTCL) of 38% (Khodadoust 2019) and peripheral T-cell lymphoma (PTCL) of 33% (Barta 2019) despite expression of PD-1/L1. These findings provide the rationale for an investigator-initiated trial of ruxolitinib added to pembrolizumab in relapsed/refractory (R/R) PTCL and CTCL, and an exploratory cohort enrolling lymphomas known to harbor 9p24.1 amplification: Hodgkin lymphoma (HL), primary mediastinal B-cell lymphoma (PMBCL), and gray zone lymphoma (GZL) (NCT07283822).

Study Design: Amping Up with PemJAK is a multi-center, phase 2, double arm, open-label trial evaluating the efficacy of ruxolitinib added to pembrolizumab in R/R PTCL and CTCL with an additional exploratory cohort in HL, PMBCL and GZL. The study is enrolling at Columbia University Irving Medical Center, with two additional subsites opening soon. The study will enroll a total of 53 patients: (Arm 1: 20 patients with PTCL; Arm 2: 23 patients CTCL; exploratory: 10 patients) across three sites. Twenty PTCL and 23 CTCL patients provide ≥80% power (one-sided α=0.1) to detect improvement compared to historical controls treated with pembrolizumab alone: complete response (CR) rate from 27% to 50% and ORR from 38% to 60%, respectively. Key inclusion criteria requires biopsy proven R/R PTCL (including PTCL-not otherwise specified, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma and subcutaneous panniculitis T-cell lymphoma), CTCL (mycosis fungoides and Sézary syndrome) or HL, PMBCL, GZL in the exploratory cohort. Patients with CD30-positive PTCL (>10%) must have received prior CD30-directed therapy. Prior treatment with anti PD-1/PDL-1 is permissible. Key exclusion criteria include adult T-Cell leukemia/lymphoma or active immunosuppression for which immunotherapy would be contraindicated. Treatment includes ruxolitinib 20mg BID with a one-week lead-in followed by combination with pembrolizumab 200mg IV every 3 weeks. Treatment will be continued until 12 months, disease progression, or intolerance. The primary endpoint is ORR in CTCL and CR rate in PTCL. Primary endpoints will be assessed by PET scan following completion of cycle 3 (prior to cycle 4) for all patients who had FDG avid nodal and/or visceral disease on baseline imaging. For patients with mycosis fungoides or Sézary syndrome, the modified severity-weighted assessment tool (mSWAT) and peripheral blood flow cytometry will occur on C4D1. Correlative studies will be performed on peripheral blood and skin punch biopsies to discern effects of JAK inhibition and combination therapy on the peripheral immune milieu and within the TME. Immune changes will be characterized by flow cytometry, CosMX spatial molecular imager (SMI), and RNA-seq. Cell-free DNA will be evaluated at baseline and C4D1 to understand utility of measurable residual disease testing in this population. Patient reported outcomes will be measured by quality-of-life surveys at baseline and C4D1. 

This trial evaluates a biologically rational, chemotherapy-free combination targeting JAK/STAT signaling and immune evasion in R/R T-cell lymphomas and 9p24.1-amplified lymphomas. Positive results could establish a novel therapeutic strategy while providing mechanistic insight through integrated translational correlatives.
Seda S. Tolu, MD: Adcetris - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony)